[
  {
    "ts": null,
    "headline": "ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)",
    "summary": "ResMedâs stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors assess both upside and downside.",
    "url": "https://finnhub.io/api/news?id=b11ce66dc77a4e994a3ee513faa0b0e15248c9dd399641cd446b3aff658519e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737730790,
      "headline": "ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)",
      "id": 132456229,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163791804/image_2163791804.jpg?io=getty-c-w1536",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "ResMedâs stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors assess both upside and downside.",
      "url": "https://finnhub.io/api/news?id=b11ce66dc77a4e994a3ee513faa0b0e15248c9dd399641cd446b3aff658519e1"
    }
  }
]